Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Aldesleukin + Cyclophosphamide + Fludarabine + IMA101 T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|IMA101 T cells||ACTolog IMA101|IMA101||IMA101 T cells are autologous cytotoxic T lymphocytes that are expanded ex vivo and injected back into the patient with the potential to recognize specific tumor-associated antigens on cancer cells and subsequently, induce cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02876510||Phase I||Aldesleukin + Cyclophosphamide + Fludarabine + IMA101 T cells||ACTolog in Patients With Solid Cancers||Active, not recruiting|